Future work should explore whether pharmacological TRPV1 antagonists, antioxidant compounds, or HIF/ERRα modulators can synergistically mitigate hypoxia-driven Ca2+ dysregulation in ERα-positive tumor models. This evidence concerns the gene ESR1 and neoplasm.